126 related articles for article (PubMed ID: 32440976)
21. A phase 3, randomized, double-blind, placebo-controlled study evaluating a single, patient-initiated dose of amenamevir for recurrent herpes labialis.
Kawashima M; Watanabe D; Fujio K; Komazaki H
J Dermatol; 2023 Mar; 50(3):311-318. PubMed ID: 36353762
[TBL] [Abstract][Full Text] [Related]
22. Antiviral Drugs Against Alphaherpesvirus.
Shiraki K
Adv Exp Med Biol; 2018; 1045():103-122. PubMed ID: 29896665
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis.
Grasela DM; Stoltz RR; Barry M; Bone M; Mangold B; O'Grady P; Raymond R; Haworth SJ
Antimicrob Agents Chemother; 2000 Aug; 44(8):2149-53. PubMed ID: 10898689
[TBL] [Abstract][Full Text] [Related]
24. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K
Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917
[TBL] [Abstract][Full Text] [Related]
25. Amenamevir: Studies of Potential CYP2C8- and CYP2B6-Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers.
Dennison J; Puri A; Warrington S; Endo T; Adeloye T; Johnston A
Clin Pharmacol Drug Dev; 2018 Nov; 7(8):860-870. PubMed ID: 29870591
[TBL] [Abstract][Full Text] [Related]
26. Aseptic Meningitis after Amenamevir Treatment for Herpes Zoster in the First Branch of the Trigeminal Nerve.
Itoh K; Mitsuke Y; Wakahara M; Yoshioka T; Otsuki N; Suzuki Y; Kiriba C; Kuwata A; Sakamaki I; Iwasaki H; Tsutani H
Intern Med; 2022 Sep; 61(18):2809-2811. PubMed ID: 35228415
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of amenamevir for the treatment of herpes zoster in an immunocompromised patient: Report of a case.
Ishiguro A; Takama H; Yanagishita T; Ohshima Y; Watanabe D
J Dermatol; 2019 Aug; 46(8):e270-e271. PubMed ID: 30897230
[No Abstract] [Full Text] [Related]
28. Integrative pharmacokinetic-pharmacodynamic modeling and simulation of amenamevir (ASP2151) for treatment of recurrent genital herpes.
Takada A; Katashima M; Kaibara A; Chono K; Katsumata K; Sawamoto T; Suzuki H; Yano Y
Drug Metab Pharmacokinet; 2016 Aug; 31(4):323-32. PubMed ID: 27461507
[TBL] [Abstract][Full Text] [Related]
29. Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus.
Chono K; Katsumata K; Suzuki H; Shiraki K
Antiviral Res; 2013 Feb; 97(2):154-60. PubMed ID: 23261844
[TBL] [Abstract][Full Text] [Related]
30. Dialyzability and pharmacokinetics of sitafloxacin following multiple oral dosing in infected hemodialysis patients.
Tsuruoka S; Yokota N; Hayasaka T; Saito T; Yamagata K
Ther Apher Dial; 2013 Jun; 17(3):319-24. PubMed ID: 23735148
[TBL] [Abstract][Full Text] [Related]
31. Single-Dose, Patient-Initiated Amenamevir Therapy for Recurrent Genital Herpes: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study.
Kawashima M; Imafuku S; Fujio K; Komazaki H
Open Forum Infect Dis; 2022 Oct; 9(10):ofac494. PubMed ID: 36267254
[TBL] [Abstract][Full Text] [Related]
32. Improvement of acyclovir-resistant herpes zoster infection by amenamevir.
Onaka T; Shiraki K; Yonezawa A
J Dermatol; 2021 Sep; 48(9):e478-e479. PubMed ID: 34137062
[No Abstract] [Full Text] [Related]
33. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
Stangier J; Rathgen K; Stähle H; Mazur D
Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
[TBL] [Abstract][Full Text] [Related]
34. Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir).
Chono K; Katsumata K; Kontani T; Shiraki K; Suzuki H
Biochem Pharmacol; 2012 Aug; 84(4):459-67. PubMed ID: 22687623
[TBL] [Abstract][Full Text] [Related]
35. Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis.
Zomorodi K; Chen D; Lee L; Lasseter K; Marbury T
J Clin Pharmacol; 2019 Aug; 59(8):1120-1129. PubMed ID: 30865315
[TBL] [Abstract][Full Text] [Related]
36. Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution in children and adolescents. Pediatric Pharmacology Research Unit Network.
Kearns GL; Abdel-Rahman SM; James LP; Blowey DL; Marshall JD; Wells TG; Jacobs RF
Antimicrob Agents Chemother; 1999 Mar; 43(3):634-8. PubMed ID: 10049279
[TBL] [Abstract][Full Text] [Related]
37. Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older.
Madkan VK; Arora A; Babb-Tarbox M; Aboutlabeti S; Tyring S
J Cutan Med Surg; 2007; 11(3):89-98. PubMed ID: 17511925
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
[TBL] [Abstract][Full Text] [Related]
39. Emergent hemodialysis for acyclovir toxicity.
Hsu CC; Lai TI; Lien WC; Chen WJ; Fang CC
Am J Emerg Med; 2005 Nov; 23(7):899-900. PubMed ID: 16291450
[No Abstract] [Full Text] [Related]
40. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
